Article Figures & Data
Figures
- Figure 1.
NK cell differentiation status in CMV-seronegative or -seropositive AML patients receiving HDC/IL2 therapy. A and B, Frequency of NKG2C+ (A) or CD57+ (B) cells among CD56dim NKG2A− KIR+ NK cells during treatment. C, Pie charts show the fraction of NK cells from CMV− and CMV+ patients that fulfill the differentiation criteria CD16+56dim > NKG2A− > KIR+ > CD57+/− > NKG2C+/−, from samples collected before immunotherapy, n = 59. D, Box plots depict percentage (%) of KIR+CD57+NKG2C+ NK cells at C1D1 and C3D1 in CMV− and CMV+ patients. E, Box plots depict percentage (%) of NS-iKIR NK cells at onset (C1D1) and during HDC/IL2 therapy in CMV− and CMV+ patients. Mann–Whitney test; box plots show 10th to 90th percentiles.
- Figure 2.
Impact of CMV serostatus on clinical outcome. A and B, Leukemia-free (A) and overall (B) survival for AML patients in the Re:Mission trial that are CMV− or CMV+. C and D, Leukemia-free (C) and overall (D) survival for a historical control cohort of nontransplanted patients with AML.
- Figure 3.
Impact of a missing ligand genotype and CMV serostatus on outcome of AML patients receiving HDC/IL2. A and B, Leukemia-free (A) and overall (B) survival for patients with a “missing ligand” or “all iKIR ligands present” genotype, and that are either CMV+ (n = 33 and 23, respectively) or CMV− (n = 17 and 8, respectively). C and D, Leukemia-free (C) and overall (D) survival of patients with a missing iKIR ligand that are CMV− compared with all other patients (n = 17 and 64, respectively).
- Figure 4.
Degranulation responses in single KIR+ NK cells. A, Frequency of CD107a+ NS-iKIR or S-iKIR NK cells in degranulation assays toward Ab-coated Daudi cells (n = 10), K562 cells (n = 10), or primary AML blasts (n = 10 and n = 14 for unstimulated and IL2-stimulated, respectively). B, Frequency of CD107a+ NS-iKIR NK cells toward Ab-coated Daudi cells in CMV− (n = 6) and CMV+ donors (n = 7). C and D, Percentage of CD107a+ NS-iKIR NK cell response of total CD107a+ NK cell response toward Ab-coated Daudi cells (C) or primary AML blasts (D) in CMV− (n = 6; C, n = 5; D) and CMV+ donors (n = 7; C, n = 5; D).
- Figure 5.
Leukemia-free survival for AML patients receiving HDC/IL2 therapy with above or below median frequency of NS-iKIR NK cells before HDC/IL2 treatment start (C1D1; A, C) or at onset of third treatment cycle (C3D1; B, D), in patients who are CMV− (A, B) or CMV+ (C, D).
Tables
- Table 1.
Univariable and multivariable analyses of the impact of CMV serostatus on LFS and OS
Univariable analysis Multivariable analysis Variable Hazard ratio Confidence interval P Hazard ratio Confidence interval P CMV serostatus LFS 0.41 0.19–0.89 0.02 0.46 0.21–1.01 0.05 CMV serostatus OS 0.26 0.08–0.87 0.03 0.28 0.08–0.96 0.04
Supplementary Data
- Supplementary information - Supplementary figures and table
Volume 6, Issue 9
